Schizophrenia is a disabling, heterogeneous disorder with clinical features that can be
parsed into three domains: positive symptoms, negative symptoms, and cognitive deficits …

The neuropeptide oxytocin (OXT) has generated considerable interest as potential treatment
for psychiatric disorders, including anxiety and autism spectrum disorders. However, the …

Standard dopamine therapies for schizophrenia are not efficacious for negative symptoms of
the disease, including asociality. This reduced social behavior may be due to glutamatergic …

Oxytocin (OT) subserves various physiological, behavioral, and cognitive processes. This
paired with the ability to administer OT with minimal and inconsistent side effects has …

The central nervous system (CNS) has, among all organ systems in the human body, the
highest failure rate of traditional small-molecule drug development, ranging from 80–100 …

Schizophrenia is a severe mental illness that causes major functional impairment. Current
pharmacologic treatments are inadequate, particularly for addressing negative and cognitive …

BackgroundThe neuropeptide oxytocin is proposed as a promising therapy for social
dysfunction by modulating amygdala-mediated social-emotional behavior. Although clinical …

Human genetic studies have recently suggested that the postsynaptic activity-regulated
cytoskeleton-associated protein (Arc) complex is a convergence signal for several genes …

Schizophrenia is a heterogeneous, debilitating disorder characterized by three distinct sets
of clinical features: positive symptoms, negative symptoms, and cognitive deficits. Extant …

Recent studies have suggested oxytocin as a possible drug to treat social deficits caused by
autism spectrum disorder (ASD), but the safety of intranasal oxytocin in autistic patients has …